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Background:  Post  licensure  studies  have  identiﬁed  an increased  risk  of intussusception  following  vaccina-
tion  with  currently  licensed  rotavirus  vaccines,  raising  safety  concerns  generic  to  all  rotavirus  vaccines.
We  describe  the surveillance  for  intussusception  in  a phase  III clinical  trial with  an  oral  monovalent
rotavirus  vaccine  developed  from  the neonatal  116E  strain.
Methods:  Using  broad  screening  criteria  and  active  surveillance,  the  incidence  of intussusception  between
6 weeks  and  2  years  of  age  was  measured  in 4532  children  who  received  three  doses  of vaccine  and  2267
children  who  received  a placebo  in the clinical  trial.  Possible  intussusceptions  were  evaluated  with  a
screening  ultrasonogram.  An independent  intussusception  case  adjudication  committee  reviewed  all
intussusceptions  and  graded  them  on  Brighton  Collaboration  criteria  for diagnostic  certainty.
Results:  We  identiﬁed  twenty-three  intussusceptions  on  ultrasound  from  1361  evaluated  sentinel  events.
Eleven  were  of  level  1 diagnostic  certainty  as  determined  by the independent  intussusception  case  adju-
dication  committee.  None  required  surgical  intervention,  and  the  earliest  identiﬁed  intussusception  was
at 36  days  following  the third  dose  in  a placebo  recipient.  Among  vaccine  recipients  the  ﬁrst  event  of  intus-
susception  occurred  112  days  after  the third  dose.  The  incidence  of  ultrasound-diagnosed  intussusception
was  200/100,000  child-years  (95%  CI, 120,  320)  among  those  receiving  the  vaccine  and  141/100,000  child-
years  (95%  CI,  50,  310)  among  those  receiving  the  placebo.  The  incidence  rate  of conﬁrmed  intussusception
among  vaccine  recipients  was  94/100,000  child-years  (95%  CI, 41, 185) and  71/100,000  child-years  (95%
CI,  15,  206)  among  those  receiving  the  placebo.
Conclusion:  In this  licensure  study,  23  cases  of  intussusception  were  identiﬁed  through  an  active  surveil-
lance  system,  but there  was no  temporal  association  with  rotavirus  vaccination.  The  use  of active
surveillance  with  broad  criteria  intended  for ensuring  safety  of  children  participating  in a trial,  identiﬁed
several  transient  intussusceptions  that  were  of  doubtful  clinical  signiﬁcance.
©  2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).. IntroductionWhile rapid strides have been made in child survival globally,
he Millennium Development Goal of reducing child mortality by
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ttp://dx.doi.org/10.1016/j.vaccine.2014.03.036
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC two thirds is unlikely to be achieved in developing countries where
acute gastroenteritis and respiratory illnesses constitute the bulk
of post neonatal under-ﬁve mortality [1]. The Integrated Global
Action Plan for the Prevention and Control of Pneumonia and Diar-
rhea recommends the introduction of rotavirus vaccines in National
Immunization Programs (NIP) along with scaling up other proven
interventions to accelerate progress in child survival [2].
A liquid oral monovalent rotavirus vaccine (Rotavac), devel-
oped from the neonatal 116E rotavirus strain, a naturally occurring
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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eassortant strain G9P [11], with one bovine gene, P[11], and 10
uman rotavirus genes through an innovative partnership, is pro-
ected to cost about one USD per dose and offers the prospect of an
ffordable rotavirus vaccine for the developing world.
Since 1999 when a tetravalent rhesus reassortant rotavirus
accine (Rotashield, Wyeth Laboratories) was withdrawn by its
anufacturer on identiﬁcation of excess risk of intussusception fol-
owing immunization [3,4], the safety of newer rotavirus vaccines
as received intense scrutiny in large licensure and post marketing
tudies. Currently licensed live rotavirus vaccines, Rotarix (Glax-
SmithKline Biologicals) and Rotateq (Merck), when evaluated in
arge phase III studies did not reveal any excess risk of intussuscep-
ion [5,6]. However post-licensure studies with both these vaccines
ave identiﬁed a smaller safety signal with 1–5 excess cases of
ntussusceptions in 100,000 immunized infants in different parts
f the world [4,7–10] leading to the need to evaluate the risk of
ntussusception with other live rotavirus vaccines.
Given the magnitude of risk seen with Rotarix and Rotateq, pre-
icensure evaluation of a similar risk would require a trial size of
everal hundred thousand infants, making development of afford-
ble vaccines difﬁcult. Hence, small risks are best evaluated in post
arketing surveillance through adverse event reporting systems
ost licensure, as recommended by national regulatory authori-
ies and the World Health Organization [11–13]. Nonetheless, in
re-licensure trials, it is critical to remain vigilant to the risk of
ntussusception in trial participants and to determine if there are
afety signals of larger magnitude than currently expected that
ight preclude licensure.
We describe the surveillance for intussusception among chil-
ren enrolled in a phase III clinical trial for safety and efﬁcacy
nd present some of the lessons learnt that might be relevant
s countries plan post marketing surveillance for intussusception
rior to or following introduction of vaccines in their NIP.
. Methods
.1. Subject recruitment and follow-up
Participants were enrolled, after written informed consent was
btained, in a phase III, double-blind placebo-controlled, random-
zed clinical trial to evaluate the efﬁcacy of three doses of Rotavac
gainst severe rotavirus gastroenteritis which was conducted at
hree sites (Delhi, Pune and Vellore) in India between 2010 and
013. The ethics review committees of participating sites approved
he protocol.
Subjects recruited between 6 and 7 weeks of age were random-
zed in a 2:1 ratio to receive 3 doses of vaccine or a placebo. Routine
hildhood vaccines were co-administered and breastfeeding was
ot restricted. The ﬁrst one third of the participants enrolled in the
tudy at all three sites were included in a detailed safety follow
hich involved study staff making daily contact for fourteen days
fter each dose of vaccine to solicit information on occurrence of
olicited adverse events.
All children recruited in the trial were also followed up weekly
ntil the age of 2 years for safety and efﬁcacy endpoints. Primary
aregivers were provided a mobile phone and access to the study
eam round the clock and were advised to contact the study team
henever the child had an episode of gastroenteritis, signs and
ymptoms of intussusception or any illness that required hospital
eferral..2. Screening and management of suspected intussusception
The study used broad screening criteria for suspected intussus-
eption to ensure all intussusceptions were identiﬁed early and(2014) A104–A109 A105
treated appropriately. All children who had three or more episodes
of vomiting in an hour or blood in stool or complaints of abdomi-
nal distension with an increase in abdominal girth of 2 cm or more
in a 4 h period or an abdominal mass palpable per abdomen were
considered to have a suspected intussusception event.
Every subject with suspected intussusception was examined by
the study team and taken for pediatric consultation and hospi-
talized, if required. Ultrasonography was  performed within eight
hours and a pediatric surgeon consulted if advised by the pedi-
atrician. Pediatric surgeons assessed children with evidence of
intussusception on ultrasonography and instituted appropriate
management as per treating facility protocol. All children who pre-
sented with blood in stool along with one other ﬁnding suggestive
of intussusception had stool samples tested for rotavirus shedding
at a central laboratory.
2.3. Adjudication of cases
An independent intussusception case adjudication commit-
tee, blinded to subject allocation reviewed clinical reports and
radiologic evidence of intussusception and adjudicated on all intus-
susceptions based on the Brighton Collaboration Intussusception
Working Group criteria for diagnostic certainty [14]. This com-
mittee was  led by a senior pediatric surgeon and had a pediatric
radiologist and a pediatrician as members. Brighton level 1 crite-
ria require the presence of surgical and/or radiologic evidence of
intussusception or the demonstration of intra abdominal mass by
abdominal ultrasound with speciﬁc characteristics, which is proven
to be reduced by hydrostatic enema on post reduction ultrasound.
2.4. Statistical methods
All children who  received at least one dose of vaccine/placebo
were included in the analysis. Incidence rate of intussusception
along with a 95% CI was calculated assuming a Poisson distribution
of events. The relative risk was  also assessed for the 7-day, 14-day,
and 60-day periods after any dose and for the 365-day period after
the ﬁrst dose.
Sensitivity and speciﬁcity of screening criteria was calculated
assuming all those who  did not have intussusception of any
diagnostic certainty as negative for intussusception and those
meeting level 1 diagnostic certainty as positive for intussuscep-
tion. The sample size of the clinical trial was  driven by efﬁcacy
considerations.
3. Results
The phase III clinical trial enrolled 6799 children across
three sites (Delhi-3799, Pune-1500, Vellore-1500), 4532 children
received vaccine and 2267 placebo. A total of 4419 (97.5%) children
in the vaccine arm and 2191 (96.6%) in the placebo arm remained in
the study till the age of two  years contributing 8506 child-years of
observation in the vaccine arm and 4248 child-years in the placebo
arm. We noted a high level of compliance to study procedures with
96.3% of the subjects receiving all three doses. The analysis included
all children who  received at least one dose of vaccine.
During the study, 1432 events of suspected intussusception
were reported in 1063 children. Of these, 46 events in 29 chil-
dren in the vaccine arm and 25 events in 18 children in the placebo
arm were based on caregiver’s complaints of abdominal distension
in the child and were unaccompanied by objective conﬁrmation
of distension or any other sign and symptom of intussusception.
Although the study team followed up the cases, no ultrasound
examination was considered necessary and medical intervention
was not required. A total of 1361 events, 914 in the vaccine group
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nd 447 in the placebo group were considered possible intussus-
eptions. These included 831 from Delhi, 111 from Pune and 419
vents from Vellore. Ultrasound examination was not performed
or 17 cases either because the family refused or because events
ere identiﬁed during routine contact with the family after the
hild had recovered. In all but four events ultrasound examinations
ere performed within eight hours of the event being identiﬁed
Fig. 1).
Blood in stool was a frequent observation with 1179 events
86.6%) in 903 children and was the primary trigger for screening for
ntussusception. Other presenting features of possible, ultrasound-
iagnosed and Brighton Level 1 intussusception are presented in
able 1.
.1. Intussusception on ultrasound examination
Investigators reported twenty-ﬁve events of intussusception
ncluding 23 identiﬁed through surveillance criteria in the proto-
ol and two that were a result of a clinical decision to perform an
ltrasound examination – one for irritability and excessive cry-
ng and the other for a child who had vomiting and abdominal
istension that did not meet the screening criteria. The intus-
usception case adjudication committee reviewed reports and
ltrasound images of 25 events of intussusception reported by site
nvestigators. The ultrasound images for two children with self-
imiting illness were of poor quality where intussusception could
ot be independently conﬁrmed. The committee adjudicated that
3 events were intussusceptions diagnosed by ultrasound exam-
nation. These included 14 male and nine female children. The
edian age at event for all ultrasound-diagnosed intussusception
as 399 days (IQR, 247, 608). The median interval between the last
ose of vaccine and the event was 280 days (IQR 137, 460). None for intussusception.
of the intussusceptions were reported in the seven, 14, 21 or 28-
day period following any vaccination. The earliest case following
immunization identiﬁed in the trial occurred in a placebo recip-
ient, 36 days after the third dose. Among those vaccinated with
Rotavac, the earliest case occurred 112 days after the third vacci-
nation. Fourteen intussusceptions (61%) occurred between seven
and 19 months of age (Fig. 2) and we  did not observe evidence of
seasonality.
The incidence of ultrasound-diagnosed intussusception was
200/100,000 child-years (95% CI, 120, 320) in the vaccine arm and
141/100,000 child-years (95% CI, 50, 310) among those receiving
placebo. The incidence of intussusception varied across geographic
locations in India with an incidence of 581 per 100,000 child-years
(95% CI 332, 943) at Vellore, 178 per 100,000 child-years (95% CI,
58, 415) at Pune and 27.7 per 100,000 child-years (95% CI, 3, 100)
at Delhi.
Twelve (52.2%) of the ultrasound-diagnosed intussusceptions
were transient and did not require medical intervention sug-
gesting an increased likelihood of picking up transient and
otherwise self-limiting small bowel intussusception of doubtful
consequence.
3.2. Conﬁrmed intussusception (Brighton level 1)
Eight events in the vaccine arm and three events in the placebo
arm had intussusception conﬁrmed at level 1 diagnostic certainty
by Brighton Collaboration Intussusception Working Group crite-
ria [14]. All 11 conﬁrmed cases of intussusception presented with
evidence of intestinal ischemia manifested as passage of blood
in stool; eight in vaccine and three in placebo groups; two  cases
of a mass palpable per abdomen on examination; both in the
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Table  1
Presenting features of children evaluated for intussusception.
Statistic Vaccine (N = 4532) Placebo (N = 2267) Total (N = 6799)
Possible
intussusception
n (%) E 688(100%) 914 328(100%) 447 1016(100%) 1361
Blood  in stool n (%) E 613 (89.1%) 789 290 (88.4%) 390 903 (88.9%) 1179
Vomiting n (%) E 91 (13.2%) 106 42 (12.8%) 49 133 (13.1%) 155
Abdominal
distention
n  (%) E 29 (4.2%) 29 12 (3.7%) 14 41 (4.0%) 43
Abdominal lump n (%) E 5 (0.7%) 5 1 (0.3%) 1 6 (0.6%) 6
USG-diagnosed
intussusception
n  (%) E 17 (100%) 17 6 (100%) 6 23 (100%) 23
Blood in stool n (%) E 11 (64.7%) 11 5 (83.3%) 5 16 (69.6%) 16
Vomiting n (%) E 6 (35.3%) 6 1 (16.7%) 1 7 (30.4%) 7
Abdominal
distention
n  (%) E 0 (0.0%) 0 1 (16.7%) 1 1 (4.3%) 1
Abdominal lump n (%) E 2 (11.8%) 2 0 (0.0%) 0 2 (8.7%) 2
Conﬁrmed
intussusception
(Brighton level 1
intussusception)
n (%) E 8(100%) 8 3 (100%) 3 11 (100%) 11
Blood in stool n (%) E 8 (100%) 8 3 (100%) 3 11 (100%) 11
Vomiting n (%) E 1 (12.5%) 1 1 (33.3%) 1 2 (18.2%) 2
Abdominal
distention
n  (%) E 0 (0.0%) 0 0 (0.0%) 0 0 (0.0%) 0
Abdominal lump n (%) E 2 (25.0%) 2 0 (0.0%) 0 2 (18.2%) 2
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t = Total number of subjects in each treatment group. n = Number of subjects with e
 = Percentages are based on the number of subjects per treatment group under eac
accine group. The amount of blood in stool was  not quantiﬁed and
e made no distinction for red currant jelly stools. Caregivers of
wo cases complained of abdominal distension in the child though
either of them had objective evidence of distension deﬁned as an
ncrease in abdominal girth by more than two cm in four hours. The
edian age at event for conﬁrmed intussusception was  250 days
IQR, 232, 504) and the duration of hospitalization three days (IQR,
,3) (Fig. 2).
Six of the conﬁrmed intussusceptions were reduced pneumat-
cally and ﬁve by barium reduction. None of the events required
urgical intervention and none were fatal. One subject had rotavirus
G1P [8]) detected in the stool sample. The sensitivity and speci-
city of screening criteria employed in this study (Table 2) suggest
hat screening for blood in stools alone would detect 69.6% of the
Fig. 2. Age distribution of in in each category.
nition. E = Number of events.
conﬁrmed cases while a screening criteria of ≥3 episodes of vomi-
ting in an hour had a speciﬁcity of 89%.
The incidence rate of conﬁrmed intussusception among vac-
cine recipients was 94/100,000 child-years (95% CI, 41, 185) and
71/100,000 child-years (95% CI, 15, 206) among those receiving
placebo. Although there was  no temporal association with vacci-
nation, even in the 2-year follow up, the difference between the
treatment arms was not statistically signiﬁcant with an odds ratio
1.34 (95% CI, 0.32, 7.82) (p = 0.76).4. Discussion
The phase III trial of the 116E vaccine was  the ﬁrst to use very
broad screening criteria and an intense and active surveillance
tussusception events.
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Table 2
Incidence of sentinel events and its validity in detecting USG diagnosed intussusception.
Incidence per 1000 child-years (95% CI) Sensitivity Speciﬁcity
Blood in stool 92.4 (87.5,97.6) 69.6% 13.2%
Vomitinga 12.2 (10.3,14.2) 30.4% 89.0%
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oBlood in stools and vomitinga 0.5 (0.2,1.0) 
Blood  in stools or vomitinga 104.1 (98.5,109.9) 
Vomiting was deﬁned as ≥ 3 episodes of vomiting in 1 h.
or intussusception. Although the study was not powered to detect
n increased risk of intussusception of the magnitude noted with
ther currently marketed rotavirus vaccines, the active follow-up
trategy resulted in the identiﬁcation of 23 cases of ultrasound
iagnosed intussusception in 6799 participants. In the REST trial
ith Rotateq, 27 cases of intussusception were observed in one
ear of follow up of 68,038 participants [6]. In the multi-country
re-licensure study of Rotarix vaccine, a median 100 day fol-
ow up after dose 1 resulted in the identiﬁcation of 25 cases of
ntussusception in 63,225 subjects [5]. An African trial identiﬁed
o cases of intussusception in 5468 subjects who participated in
otateq trials [15] with a median follow up of 527 days starting
4 days after the third dose. Rotateq trials in Asia identiﬁed one
ase on ultrasonography among 2036 infants followed up [16].
ne case of intussusception was identiﬁed in 4939 infants fol-
owed to one year of age in Rotarix trials in Africa [17]. These data
ndicate that study protocols for screening and follow up impact
he ability of investigative teams to identify cases of intussuscep-
ion.
In the 116E trial, we considered identifying all possible cases
f intussusception in this community based placebo-controlled
linical trial an ethical priority. The study employed very broad
creening criteria to identify potential cases early and evaluated
hem using standard diagnostic tools. For instance, 13.5% of chil-
ren experienced an event of blood in stools with an incidence rate
n the trial cohort of 92.4 per 1000 child-years (95% CI, 87.2, 97.9).
he use of these broad criteria for active surveillance resulted in
any children with non-speciﬁc illness being screened at a hos-
ital and undergoing an ultrasound examination. The screening
rotocol resulted in only 1.6% of the possible cases being classi-
ed as ultrasound-evidenced intussusception and 0.8% Brighton
evel 1 conﬁrmed intussusception. Based on this study, the broad
creening approach met  the safety criterion of protecting children
articipating in the trial by ensuring that every case was  detected
nd managed quickly. However, this required intense effort from
he study teams, and resulted in identiﬁcation of a large propor-
ion of transient cases, illustrating the difﬁculties in diagnosing
ases that could have resulted in a need for intervention in routine
ractice versus incident cases of any severity. This suggests that
riteria employed in the trial are inefﬁcient for any form of routine
urveillance for intussusception, and future trials may  rely on the
assive surveillance employed for previous large safety studies.
The incidence rate of ultrasound-diagnosed intussusception of
40/100,000 child-years in the placebo arm is higher than most
bservational studies but consistent with recent data from Vietnam
18] and is likely attributable to the low threshold for ultrasound
valuation of a potential case.
In the 116E study, the earliest intussusception event in a vacci-
ated child was 112 days after the third dose. The lack of temporal
ssociation between vaccination and event among those vaccinated
uggests a causal relationship is very unlikely for cases identiﬁed
n this trial, but does not preclude a risk similar to that seen with
vailable licensed vaccines.Rotavirus vaccines are recommended for global use by the
orld Health Organization [19] and evidence from both developing
nd developed countries demonstrates the impact of these vaccines
n disease reduction in young children [20–23]. Increased risk of8.7% 99.7%
91.3% 2.46%
intussusception has been detected in Australia, Mexico, Brazil and
the USA, but the risks of intussusception outweigh the potential
beneﬁts of vaccination in disease and mortality reduction, particu-
larly in areas where diarrheal disease continues to be a major killer
of children. Nonetheless, monitoring safety will continue to be crit-
ical both pre-licensure and after introduction because vaccination
safety at the level of the individual child and of programs is neces-
sary to manage rare side effects and to prevent undue harm from
newly developed vaccines.
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